How it works
Albuterol, known as salbutamol outside the US, is a fast-acting medicine that opens up narrowed airways. The muscles wrapping around the breathing tubes can tighten and squeeze the airways shut, as happens in an asthma attack. Albuterol tells those muscles to relax, widening the passages so air moves more freely.
It does this by mimicking the body's own 'fight or flight' signals at a specific docking site called the beta-2 receptor, which is concentrated in airway muscle. Because it acts quickly and wears off within a few hours, it is the classic 'rescue inhaler' used to relieve sudden symptoms, rather than a controller medication taken to prevent them long term. It is most often inhaled so the drug acts directly on the lungs with less reaching the rest of the body.
Albuterol is FDA-approved and a mainstay of asthma and chronic obstructive pulmonary disease care. Common side effects reflect spillover stimulation elsewhere in the body, such as tremor, a faster heartbeat, and jitteriness. Frequent need for a rescue inhaler can signal poorly controlled disease and warrants medical review.
Mechanism · Detailed Analysis
Molecular targetAlbuterol is a selective agonist of the beta-2 adrenergic receptor, a Gs-coupled GPCR densely expressed on airway smooth muscle. Selectivity for beta-2 over beta-1 receptors is relative rather than absolute, so cardiac and systemic beta effects emerge at higher exposures. It is administered as a racemate, with the (R)-enantiomer (levalbuterol) carrying the bronchodilator activity.
Signaling & downstream effectsReceptor activation stimulates adenylate cyclase via Gs, raising cAMP and activating protein kinase A. This lowers intracellular calcium and inhibits myosin light-chain kinase activity, producing relaxation of bronchial smooth muscle and bronchodilation. Beta-2 stimulation also drives potassium into cells, which underlies both a notable side effect (hypokalemia) and an off-label use in hyperkalemia.
PharmacokineticsBy the inhaled route bronchodilation begins within minutes and lasts on the order of a few hours, defining its short-acting profile; oral and intravenous forms exist but are less commonly used. It is metabolized largely by sulfotransferase conjugation rather than the cytochrome P450 system. The drug is also available via nebulizer for more severe presentations.
CaveatsDose-related systemic effects include tremor, tachycardia, palpitations, and hypokalemia, with caution warranted in cardiovascular disease, arrhythmia, and hyperthyroidism. Overreliance on short-acting beta-agonists reflects inadequate asthma control and is associated with worse outcomes. Paradoxical bronchospasm is a rare but recognized reaction.
Published EvidenceLoading cited studies from PubMed…
Human Data ···
Searching the published record…
Animal ···
Searching the published record…
In Vitro ···
Searching the published record…
Educational aggregation of public literature. Not medical advice and not a recommendation to use any compound. Many compounds here are not approved for human use. Consult a licensed clinician.